-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Revolution Medicines, Raises Price Target to $265

Benzinga·08/28/2026 16:37:36
Listen to the news
UBS analyst Michael Yee maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $220 to $265.